All In Biotech

Drug Trial Radar · NCT03636269

CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus

A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Intravenous CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus, With a 52-Week Open Label Extension

Last checked: Nov 19, 2026Latest source record: Apr 26, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 473 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

473

Actual

Start

Jul 17, 2018

Primary completion

Mar 30, 2020

Study completion Mar 30, 2020

Sponsor

Lead sponsor
Cara Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Aug 17, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, international study to evaluate the safety and efficacy of intravenous (IV) CR845 at a dose of 0.5 mcg/kg administered after each dialysis session. The study includes a 12-week randomized, double-blind, placebo-controlled Phase and a 52-week Open-label Extension Phase.

Conditions

  • Uremic Pruritus

Interventions

  • CR845 0.5 mcg/kgDrug

    IV CR845 0.5 mcg/kg administered three times/week

  • PlaceboDrug

    IV placebo administered three times/week

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Reduction of Itch Intensity as Assessed by the Percentage of Patients Achieving an Improvement From Baseline ≥3 Points With Respect to the Weekly Mean of the Daily 24-hour Worst Itching Intensity Numerical Rating Scale (NRS) Score at Week 12Time frame: Week 12

Locations

92 sites in 11 countries. Site status is shown where the registry gives one.

  • Cara Therapeutics Study Site

    Chula Vista, California

  • Cara Therapeutics Study Site

    Fountain Valley, California

  • Cara Therapeutics Study Site

    Northridge, California

  • Cara Therapeutics Study Site

    Riverside, California

  • Cara Therapeutics Study Site 2

    San Dimas, California

  • Cara Therapeutics Study Site

    San Dimas, California

  • Cara Therapeutics Study Site

    Westminster, Colorado

  • Cara Therapeutics Study Site

    Hialeah, Florida

  • Cara Therapeutics Study Site

    Miami Gardens, Florida

  • Cara Therapeutics Study Site

    Orlando, Florida

  • Cara Therapeutics Study Site

    Athens, Georgia

  • Cara Therapeutics Study Site

    Macon, Georgia

  • Cara Therapeutics Study Site

    Baton Rouge, Louisiana

  • Cara Therapeutics Study Site

    Brockton, Massachusetts

  • Cara Therapeutics Study Site

    Kalamazoo, Michigan

  • Cara Therapeutics Study Site

    Roseville, Michigan

  • Cara Therapeutics Study Site

    Saint Clair, Michigan

  • Cara Therapeutics Study Site

    Tupelo, Mississippi

  • Cara Therapeutics Study Site

    St Louis, Missouri

  • Cara Therapeutics Study Site

    Clifton, New Jersey

  • Cara Therapeutics Study Site

    Somerville, New Jersey

  • Cara Therapeutics Study Site

    Albuquerque, New Mexico

  • Cara Therapeutics Study Site

    Long Island City, New York

  • Cara Therapeutics Study Site

    Austin, Texas

  • Cara Therapeutics Study Site

    Dallas, Texas

  • Cara Therapeutics Study Site

    McAllen, Texas

  • Cara Therapeutics Study Site

    San Antonio, Texas

  • Cara Therapeutics Study Site

    St. George, Utah

  • Cara Therapeutics Study Site

    Roanoke, Virginia

  • Cara Therapeutics Study Site

    Adelaide, Australia

  • Cara Therapeutics Study Site

    Camperdown, New South Wales, Australia

  • Cara Therapeutics Study Site

    Concord, New South Wales, Australia

  • Cara Therapeutics Study Site

    Wahroonga, New South Wales, Australia

  • Cara Therapeutics Study Site

    Westmead, New South Wales, Australia

  • Cara Therapeutics Study Site

    Launceston, Tasmania, Australia

  • Cara Therapeutics Study Site

    Clayton, Victoria, Australia

  • Cara Therapeutics Study Site

    Heidelberg, Victoria, Australia

  • Cara Therapeutics Study Site

    St Albans, Victoria, Australia

  • Cara Therapeutics Study Site

    Halifax, Nova Scotia, Canada

  • Cara Therapeutics Study Site

    Oshawa, Ontario, Canada

Showing 40 of 92 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.